Table 2. Incidence and maximum toxicity observed during CapIri-RT treatment (n=36 patients).
Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
---|---|---|---|---|
Haematologic | ||||
Leucocytopenia | 12 | 7 | 7 | 2 |
Thrombocytopenia | 2 | — | — | — |
Anaemia | 23 | 9 | — | — |
Gastrointestinal | ||||
Nausea/vomiting | 9 | 10 | 2 | — |
Mucositis/stomatitis | 2 | — | — | — |
Diarrhoea | 13 | 15 | 4 | — |
Proctitis | 11 | 4 | — | — |
Abdomial cramping | 6 | 4 | — | — |
Laboratory | ||||
Hyperbilirubinaemie | 2 | 1 | — | — |
ALAT/ASAT elevation | 3 | 3 | 1 | — |
Creatinine elevation | 3 | — | — | — |
Skin | ||||
Hand-foot skin reaction | 3 | — | — | — |
Alopecia | 5 | — | — | — |
Radiation dermatits | 12 | 7 | — | — |
Other | ||||
Fatigue | 11 | 6 | 1 | — |
Cholinergic syndrome | 2 | — | — | — |
CTC, common toxicity criteria; NCI, National Cancer Institute.
Adverse events are graded according to CTC of the NCI version 2.0.